Anti-Cancer Antibodies
Anticancer antibodies has created great interest in antibody-based therapeutics for hematopoietic malignant neoplasms and solid tumors. Given the likelihood of lower toxic effects of antibodies that target tumor cells and have limited impact on nonmalignant bystander organs vs small molecules, the potential increased efficacy by conjugation to radioisotopes and other cellular toxins, and the ability to characterize the target with clinical laboratory diagnostics to improve the drug's clinical performance, current and future antibody therapeutics are likely to find substantial roles alone and in combination therapeutic strategies for treating patients with cancer. Therapeutic antibodies have become a major strategy in clinical oncology owing to their ability to bind specifically to primary and metastatic cancer cells with high affinity and create antitumor effects by complement-mediated cytolysis and antibody-dependent, cell-mediated cytotoxicity (naked antibodies) or by the focused delivery of radiation or cellular toxins (conjugated antibodies).
- Antibodies in Treatment of Cancer
- Characterizing and clinical use of Circulating Tumor Cells (CTCS)
- Advances in tumor modeling, cancer drug discovery and development
- Translational approaches in cancer immunotherapy development
- Innovative in vitro and in vivo modeling
Related Conference of Anti-Cancer Antibodies
5th International conference on Vaccines, Vaccination and Immunization
Anti-Cancer Antibodies Conference Speakers
Recommended Sessions
- Anti-Cancer Antibodies
- Antibiotics
- Antibiotics used in Industries
- Antibiotics: Advances in Treatment
- Antibiotics: Applications
- Antibiotics: Clinical Trials
- Antibiotics: Infectious Diseases
- Antibiotics: Mechanism of Action
- Antibodies: Infectious Diseases
- Antibodies: Medical Applications
- Antibody Conjugate Therapeutics: Challenge and Potential
- Antibody Drug Therapy
- Antibody Engineering
- Antibody Humanization Technologies
- Auto Immune Antibodies
- Bio therapeutics : Early Analytical Development
- Bio Therapeutics: Novel Formulation and Delivery Approaches
- Cancer Immune therapy
- Emerging Protein Bio Therapeutics
- Immunotherapy and Immune Checkpoints
- Monoclonal Antibody Therapy
- Next-Generation Sequencing(NGS) in Antibody Discovery and Engineering: Overview and Applications
- Protein Engineering and Genetic Engineering
Related Journals
Are you interested in
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)